Skip to main content

Beckman Coulter Buys Flow Cytometry Firm Blue Ocean Biomedical

NEW YORK (GenomeWeb News) – Beckman Coulter Life Sciences announced late Thursday it has acquired flow cytometry firm Blue Ocean Biomedical for an undisclosed amount.

According to Beckman Coulter, the deal provides it with low complexity analyzers that integrate automated sample preparation. It added the acquisition will allow it to directly address emerging flow cytometry market trends.

Blue Ocean's instruments are based on a "sample in, result out," or SIRO, approach that Beckman said represents "a fundamental change in the routine clinical analysis sector." Its SIRO solution is the only one for clinical flow cytometry.

"This acquisition provides both immediate opportunity and long-term value," Scott Atkin, president of Beckman Coulter Life Sciences, said in a statement. "The simplification of customer workflows will be dramatic. We'll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry."

Blue Ocean is based in Pembroke Pines, Fla.

Beckman Coulter Life Sciences is part of Beckman Coulter, which was acquired last year by Danaher for $6.8 billion.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.